Guangzhou Institute of Biomedicine and Health-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Guangzhou Institute of Biomedicine and Health - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013276
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Guangzhou Institute of Biomedicine and Health (GIBH) is a research institute that conducts research on stem cell and regenerative medicine, chemical biology, infection and immunity, public health and scientific research equipment development. The institute’s life process and disease mechanism provide solutions to the innovation and integration of human health and disease prevention, constructing research and development base for China’s bio-medicine and health and serving national strategic demands and economic and social development. It provides mechanisms for controlling the transformation of adult cells into pluripotent stem cells (iPSCs) and optimization of protocols for directed differentiation of normal and diseased human iPSCs into different cell lineages. GIBH is headquartered in Guangzhou, China.

Guangzhou Institute of Biomedicine and Health – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Euclises Pharma Enters into Co-Development Agreement with Guangzhou Institutes of Biomedicine 10
Casigen Pharma Enters Into Co-Development Agreement With Guangzhou Institute of Biomedicine and Health 11
Ventac Partners Enters Into Joint Venture Agreement With Guangzhou Institutes of Biomedicine 12
Saint Louis University Enters Into Co-Development Agreement With Guangzhou Institute 13
Licensing Agreements 14
RaQualia Enters Into Licensing And Co-Development Agreement With A Chinese Company And Guangzhou Institutes of Biomedicine 14
Guangzhou Institute of Biomedicine and Health – Key Competitors 15
Guangzhou Institute of Biomedicine and Health – Key Employees 16
Guangzhou Institute of Biomedicine and Health – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
Joint Venture 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Key Facts 2
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Guangzhou Institute of Biomedicine and Health, Deals By Therapy Area, 2011 to YTD 2017 8
Guangzhou Institute of Biomedicine and Health, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Euclises Pharma Enters into Co-Development Agreement with Guangzhou Institutes of Biomedicine 10
Casigen Pharma Enters Into Co-Development Agreement With Guangzhou Institute of Biomedicine and Health 11
Ventac Partners Enters Into Joint Venture Agreement With Guangzhou Institutes of Biomedicine 12
Saint Louis University Enters Into Co-Development Agreement With Guangzhou Institute 13
RaQualia Enters Into Licensing And Co-Development Agreement With A Chinese Company And Guangzhou Institutes of Biomedicine 14
Guangzhou Institute of Biomedicine and Health, Key Competitors 15
Guangzhou Institute of Biomedicine and Health, Key Employees 16
Guangzhou Institute of Biomedicine and Health, Joint Venture 17

★海外企業調査レポート[Guangzhou Institute of Biomedicine and Health-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Support.com, Inc. (SPRT):企業の財務・戦略的SWOT分析
    Support.com, Inc. (SPRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Reviva Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Reviva Pharmaceuticals Inc (Reviva Pharma) is a clinical development pharmaceutical company that develops therapeutic drugs. The company develops drugs in the therapeutic areas of cardiovascular, metabolic, central nervous system and inflammatory diseases. Its product pipeline comprises RP50 …
  • Kronos Worldwide Inc (KRO):企業の財務・戦略的SWOT分析
    Kronos Worldwide Inc (KRO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Noni B Ltd (NBL):企業の財務・戦略的SWOT分析
    Noni B Ltd (NBL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • BioDelivery Sciences International Inc (BDSI):企業の財務・戦略的SWOT分析
    BioDelivery Sciences International Inc (BDSI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Coca-Cola FEMSA SAB de CV:企業の戦略・SWOT・財務情報
    Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola FEMSA SAB de CV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vertical Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Vertical Pharmaceuticals LLC (Vertical Pharmaceuticals), a subsidiary of Osmotica Pharmaceutical Corp, is a medicines marketing company that supplies niche prescription medicines. The company offers product category includes women's health and pain management. It provides products such as Co …
  • Thaivivat Insurance Public Company Limited:企業の戦略・SWOT・財務分析
    Thaivivat Insurance Public Company Limited - Strategy, SWOT and Corporate Finance Report Summary Thaivivat Insurance Public Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, …
  • U.S. Smokeless Tobacco Company:企業の戦略・SWOT・財務分析
    U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report Summary U.S. Smokeless Tobacco Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Microbix Biosystems Inc (MBX):企業の財務・戦略的SWOT分析
    Summary Microbix Biosystems Inc (Microbix) is a provider of biological and technology solutions for human health and wellbeing. The company's products include infectious disease antigens and quality assessment products. It manufactures viral and bacterial antigens and reagents for the diagnostics. M …
  • PCL Constructors Inc:企業の戦略的SWOT分析
    PCL Constructors Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Mobile Telesystems
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • The Kyoto Hotel, Ltd.:企業の戦略・SWOT・財務分析
    The Kyoto Hotel, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Kyoto Hotel, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fidelity Bank Plc:企業の戦略・SWOT・財務情報
    Fidelity Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Fidelity Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sanofi Genzyme:企業のM&A・事業提携・投資動向
    Sanofi Genzyme - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Sanofi Genzyme Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • Bank of Singapore Ltd.:企業の戦略・SWOT・財務情報
    Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of Singapore Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Shanghai Kehua Bio-engineering Co Ltd (002022):企業の財務・戦略的SWOT分析
    Shanghai Kehua Bio-engineering Co Ltd (002022) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key str …
  • Eyevensys SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Eyevensys SAS (Eyevensys) is a clinical stage biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its lead product, EYS-606, is a soluble TNFa receptor plasmid associated with the ETIS device to treat non-infectious intermediate and posterior uveitis(NIU); EYS- …
  • NewLink Genetics Corp (NLNK):製薬・医療:M&Aディール及び事業提携情報
    Summary NewLink Genetics Corp (NewLink) is a clinical stage immuno-oncology company that discovers and develops novel immunotherapeutic products for the treatment of cancer. Its products include small-molecule and biologic immuno-oncology products. NewLink utilizes its HyperAcute cellular immunother …
  • Tootsie Roll Industries, Inc.:企業の戦略・SWOT・財務情報
    Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Tootsie Roll Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆